Sarepta Therapeutics Anticipates 32% YOY Growth with Successful Execution of Three RNA-Based PMO Treatments
January 10, 2023
Trending News ☀️
Sarepta Therapeutics ($NASDAQ:SRPT) is a biopharmaceutical company that has been researching, developing and commercializing therapies for rare neuromuscular diseases. They are dedicated to providing meaningful advances in the lives of those affected by these diseases. On Monday, Sarepta Therapeutics made an announcement that they anticipate 32% year-over-year growth with successful execution of their three RNA-based PMO treatment therapies. This will result in .2M revenue for the company. All three treatments are based on Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology. The treatments work by targeting and skipping over specific genetic mutations that lead to the development of the disease.
The successful execution of these three RNA-based PMO treatments is expected to bring substantial revenue growth for Sarepta Therapeutics, as well as a positive impact on the lives of those affected by these diseases. Since then, many patients have seen positive results from these treatments, with some experiencing improved muscle strength and function. Sarepta Therapeutics’ announcement on Monday has caused a surge in the stock price of the company, as investors anticipate the 32% YOY growth that is expected with the success of these treatments. The company’s dedication to finding treatments for rare neuromuscular diseases has resulted in significant progress and is likely to continue to increase their profits as well as positively impacting the lives of those affected by these diseases.
Market Price
Currently, the media sentiment is mostly positive towards the company. On Monday, SAREPTA THERAPEUTICS stock opened at $123.0 and closed at $117.5, a decrease of 3.9% from its last closing price of 122.3. DMD is an incurable genetic disorder that affects muscle strength, leading to progressive muscle weakness and eventually death. The new treatments have the potential to improve quality of life for patients with DMD. The company is also working on developing treatments for other rare diseases such as myotonic dystrophy type 1 and limb-girdle muscular dystrophy type 2E. Sarepta Therapeutics has also partnered with several other companies to develop treatments for rare and ultra-rare diseases. The success of Sarepta Therapeutics’ treatments could lead to a major breakthrough in the healthcare industry.
These treatments could potentially lead to improved quality of life for those affected by rare and ultra-rare diseases. If the company’s treatments are successful, it could be a major win for Sarepta Therapeutics and the medical field as a whole. The company’s stock may have experienced a 3.9% drop on Monday, but this does not detract from the potential success of the company’s treatments. With continued hard work and dedication, Sarepta Therapeutics could revolutionize the healthcare industry with its groundbreaking treatments. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sarepta Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 876.05 | -716.23 | -73.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sarepta Therapeutics. More…
| Operations | Investing | Financing |
| -262.28 | -1.06k | 771.01 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sarepta Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.16k | 2.73k | 4.91 |
Key Ratios Snapshot
Some of the financial key ratios for Sarepta Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 33.9% | – | -50.3% |
| FCF Margin | ROE | ROA |
| -32.8% | -47.6% | -8.7% |
VI Analysis
Sarepta Therapeutics is a company with strong potential in the long term, as reflected in its fundamentals. This is made simple to analyze by the VI app, which categorizes the company as a “cheetah” – a type of company that achieves high revenue or earnings growth but is considered less stable due to lower profitability. The VI Star Chart shows that Sarepta Therapeutics is strong in growth, medium in asset and weak in dividend and profitability. Investors who are looking for high growth potential and are willing to take on higher risk may be interested in investing in Sarepta Therapeutics. However, its low health score of 2/10 considering cashflows and debt might suggest that it is less likely to sustain future operations in times of crisis. Therefore, it is important to do thorough research and analysis before investing in such a company. Overall, Sarepta Therapeutics reflects a strong potential for the long term, but investors should assess the risks involved before investing. Investors who are willing to take on higher risk may find opportunities in this company, but should keep an eye out for potential issues in the future. More…
VI Peers
The company is headquartered in Cambridge, Massachusetts and was founded in 1980. Sarepta Therapeutics Inc has four main competitors: Genor Biopharma Holdings Ltd, Impel Pharmaceuticals Inc, Entera Bio Ltd, and PTC Therapeutics Inc. These companies are all focused on the development of treatments for DMD and other rare diseases.
– Genor Biopharma Holdings Ltd ($SEHK:06998)
Genor Biopharma Holdings Ltd is a pharmaceutical company that focuses on the development and commercialization of innovative drugs for the treatment of cancer. The company has a market cap of 949.11M as of 2022 and a ROE of -23.99%. The company’s products are designed to target specific genetic mutations that are known to drive the growth and progression of cancer.
– Impel Pharmaceuticals Inc ($NASDAQ:IMPL)
Impel Pharmaceuticals Inc is a pharmaceutical company with a market cap of 94.72M as of 2022. The company has a Return on Equity of -359.89%. Impel Pharmaceuticals Inc is a company that focuses on the development and commercialization of drugs for the treatment of central nervous system disorders.
– Entera Bio Ltd ($NASDAQ:ENTX)
Entera Bio Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of oral therapeutics for serious unmet medical needs. The company’s lead product candidate is EB614, an oral biologic that is in clinical development for the treatment of osteoporosis, inflammatory bowel disease, and other immune-mediated diseases. Entera Bio Ltd has a market cap of 24.06M as of 2022, a Return on Equity of -48.6%. The company’s focus on the development and commercialization of oral therapeutics makes it a unique player in the biopharmaceutical market. However, its negative ROE indicates that it is not a profitable company at this time.
Summary
Sarepta Therapeutics has seen positive media sentiment and anticipates 32% year-over-year growth due to their successful execution of three RNA-based PMO treatments. Despite this, the stock price has seen a decrease in value. Investors may be hesitant to invest in the company as the effects of the treatments have yet to be seen. It is important to note, however, that the treatments have been successfully executed and could provide long-term growth potential for Sarepta Therapeutics.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
